• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

If Dapa is doomed













The "Fat Lady" is standing at the microphone, clearing her bovine-like throat and beginning to sing the first an only verse of "Another One Bites The Dust"........Que sera sera
 




Someone still has to sell onglyza and kombiglyze - and it ain't gonna be the CV team - they will be in launch mode. Get rid of the contract people, and tell AZ it's been nice, but we're done. Oh, and hope for Ticagrelor!!
 




Someone still has to sell onglyza and kombiglyze - and it ain't gonna be the CV team - they will be in launch mode. Get rid of the contract people, and tell AZ it's been nice, but we're done. Oh, and hope for Ticagrelor!!

I agree. inVentiv reps will be gone in September (end of Q3)... Sorry, but there's just no need. Don't know about AZ, but saying goodbye there might not be such a bad idea.
 




Okay children, let's look at the facts. So far Ong Kom is not sustainable to pick up the lost revenue when Plavix loses LOE. Maybe dapa will get approved. Best case is with a BBW for cancer if at all. Metformin got launched with a BBW for lactic acidosis. It then became the gold standard. At some point there will be an assessment for the # of PDE's needed. This will determine headcount in CV. If dapa is a no-go.......well you get the point....
 




Okay children, let's look at the facts. So far Ong Kom is not sustainable to pick up the lost revenue when Plavix loses LOE. Maybe dapa will get approved. Best case is with a BBW for cancer if at all. Metformin got launched with a BBW for lactic acidosis. It then became the gold standard. At some point there will be an assessment for the # of PDE's needed. This will determine headcount in CV. If dapa is a no-go.......well you get the point....

But you still need reps to sell Onglyza/Kombi. Just make it 1 rep/territory, and there is enough to keep us in jobs.
 




Okay children, let's look at the facts. So far Ong Kom is not sustainable to pick up the lost revenue when Plavix loses LOE. Maybe dapa will get approved. Best case is with a BBW for cancer if at all. Metformin got launched with a BBW for lactic acidosis. It then became the gold standard. At some point there will be an assessment for the # of PDE's needed. This will determine headcount in CV. If dapa is a no-go.......well you get the point....

"Ong Kom is not sustainable to pick up lost revenue when Plavix loses LOE." - NO SHIT Sherlock! $160 million vs $7 BILLION.

"Maybe dapa will get approved." - Maybe monkeys will fly out YOUR ass.

"Best case is BBW for cancer if at all." - Keep wishing and hoping, singing and praying.

Metformin was launched when the only options were insulin and SUs, a whole different world than today for type 2 patients.

There is no reason on earth for a medium efficacy drug with serious potential safety issues (liver failure and CANCER) to be approved without at least another 2-3 year safety study.

Push it in the grave, it is dead.

Now just sit back and watch the BMS spin machine go into fucking action, it will be amusing!!!!
 




"Ong Kom is not sustainable to pick up lost revenue when Plavix loses LOE." - NO SHIT Sherlock! $160 million vs $7 BILLION.

"Maybe dapa will get approved." - Maybe monkeys will fly out YOUR ass.

"Best case is BBW for cancer if at all." - Keep wishing and hoping, singing and praying.

Metformin was launched when the only options were insulin and SUs, a whole different world than today for type 2 patients.

There is no reason on earth for a medium efficacy drug with serious potential safety issues (liver failure and CANCER) to be approved without at least another 2-3 year safety study.

Push it in the grave, it is dead.

Now just sit back and watch the BMS spin machine go into fucking action, it will be amusing!!!!

Do you ever read your professional posts? You sound like a nut. Foul mouthed and unbalanced.